The biologic is the first drug that aims to delay the diagnosis of type 1 diabetes. The FDA Thursday approved teplizumab, the first drug to delay the onset of type 1 diabetes (T1D). Teplizumab, a ...

This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. On one wall of endocrinologist Kevan Herold’s ...

The American Diabetes Association's chief scientific and medical officer said the results are important to families at risk of type 1 diabetes. Recent studies involving teplizumab, which is currently ...

Teplizumab (Tzield) infusions in children and adolescents with new-onset type 1 diabetes met the primary endpoint of preserved beta-cell function and trended toward improved secondary glycemic ...

Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin. The Food and Drug Administration (FDA) has ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

MacroGenics and Eli Lilly announced that they achieved their targeted patient enrollment for their Phase 2/3 PROTEGE trial evaluating teplizumab for the treatment of recent-onset type 1 diabetes. The ...

TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds the decision from the U.S Food and Drug Administration (FDA) to ...

Diabetes researchers tend to be masters of understatement, but now they seem to be universally excited about a new drug that some are even calling “revolutionary” because it can delay the onset of ...

Please provide your email address to receive an email when new articles are posted on . Children recently diagnosed with type 1 diabetes had a higher C-peptide level at 78 weeks with teplizumab vs.